1241 related articles for article (PubMed ID: 21605038)
1. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of tau self-aggregation and neurotoxicity.
Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
[TBL] [Abstract][Full Text] [Related]
3. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
4. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
Moore KBE; Hung TJ; Fortin JS
Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
[TBL] [Abstract][Full Text] [Related]
6. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
7. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
8. The Neurotoxic Role of Extracellular Tau Protein.
Sebastián-Serrano Á; de Diego-García L; Díaz-Hernández M
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584657
[TBL] [Abstract][Full Text] [Related]
9. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.
Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Sarmiento J; Troncoso J; Jackson GR; Kayed R
FASEB J; 2012 May; 26(5):1946-59. PubMed ID: 22253473
[TBL] [Abstract][Full Text] [Related]
10. Granular tau oligomers as intermediates of tau filaments.
Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
[TBL] [Abstract][Full Text] [Related]
11. Tau as a therapeutic target for Alzheimer's disease.
Boutajangout A; Sigurdsson EM; Krishnamurthy PK
Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
[TBL] [Abstract][Full Text] [Related]
12. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
13. Structure of NFT: Biochemical Approach.
Hasegawa M
Adv Exp Med Biol; 2019; 1184():23-34. PubMed ID: 32096025
[TBL] [Abstract][Full Text] [Related]
14. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
16. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
[TBL] [Abstract][Full Text] [Related]
17. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
18. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
[TBL] [Abstract][Full Text] [Related]
19. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
20. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
